Observational studyAnnals of Saudi medicine
Malignancy in patients with acromegaly: a multicenter study across the Gulf region.
Observational study in Annals of Saudi medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic growth hormone and insulin-like growth factor 1 excess may promote tumorigenesis, but the magnitude of malignancy risk in acromegaly remains uncertain and regional data from the Gulf are limited.
objectiveTo describe the frequency, spectrum, detection, outcomes, and clinical correlates of malignancy among patients with acromegaly treated across Gulf tertiary centers.
designMulticenter retrospective observational study.
settingFive tertiary centers across Saudi Arabia, Qatar, and the United Arab Emirates. PATIENTS AND
methodsMedical records of patients aged >16 years with acromegaly who were evaluated from 2010 through 2024 were reviewed. Demographic, disease, treatment, cancer-testing, and malignancy data were collected. Group comparisons were descriptive and exploratory because only 10 malignancies occurred.
main outcome measuresDocumented malignancy frequency, cancer type, method of detection, stage, treatment, outcome, and clinical correlates. SAMPLE SIZE: 157 patients.
resultsThe mean age was 47.1 years, 101 patients (64.3%) were male, and the mean disease duration was 9.4 years. Malignancy was documented in 10 patients (6.4%), most commonly papillary thyroid carcinoma (8/10). Two of the eight papillary thyroid carcinomas were classified as T1a (≤10 mm); exact pathology measurements were not consistently available. One patient had colorectal cancer, and one had prostate cancer. Exploratory comparisons showed that patients with malignancy were older than those without malignancy (mean age, 56.6 vs 46.5 years;
conclusionMalignancy was documented in 6.4% (10 out of 157) in this multi-center Gulf acromegaly cohort, predominantly papillary thyroid carcinoma. The findings support individualized surveillance based on population guidance, symptoms, family history, and clinical findings rather than an acromegaly-specific screening program. LIMITATIONS: Retrospective design, small number of malignancy events, missing data, lack of a population comparator, and nonstandardized cancer testing may introduce selection and detection biases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.